Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study.
Kasper
S
S
Department of General Psychiatry, University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria. SK@akh-wien.ac.at
D018759:Adrenergic Uptake Inhibitors / Q000009:adverse effects*; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects*; D003865:Major Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000009:adverse effects*; D000077593:Reboxetine; D013449:Sulfonamides / Q000627:therapeutic use; D000077409:Tamsulosin; D016055:Urinary Retention / Q000139:chemically induced* / Q000188:drug therapy
D018759:Adrenergic Uptake Inhibitors; D000317:Adrenergic alpha-Antagonists; D000928:Antidepressive Agents; D009025:Morpholines; D013449:Sulfonamides; D000077593:Reboxetine; D000077409:Tamsulosin